News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
584,544 Results
Type
Article (33823)
Company Profile (557)
Press Release (550148)
Multimedia
Podcasts (165)
Webinars (20)
Section
Business (173204)
Career Advice (1877)
Deals (29275)
Drug Delivery (178)
Drug Development (72499)
Employer Resources (107)
FDA (13912)
Job Trends (12320)
News (268309)
Policy (24900)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (2)
2027 BioMidwest Elite (2)
2027 BioMidwest Standard (2)
2027 Bio NC Standard (3)
2027 Biotech Bay Elite (4)
2027 Biotech Bay Standard (7)
2027 Biotech Beach Digital (1)
2027 Biotech Beach Elite (3)
2027 Biotech Beach Standard (5)
2027 Genetown Elite (5)
2027 Genetown Standard (11)
2027 Pharm Country Digital (1)
2027 Pharm Country Elite (2)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (8)
Academia (2236)
Academic (2)
Accelerated approval (67)
ADA (51)
Adcomms (30)
Allergies (196)
Alliances (33993)
ALS (249)
Alzheimer's disease (1749)
Antibody-drug conjugate (ADC) (624)
Approvals (14525)
Artificial intelligence (843)
ASCO (333)
Autoimmune disease (412)
Automation (60)
Bankruptcy (265)
Belgium (10)
Best Places to Work (9844)
BIO (80)
Biologics (16)
BIOSECURE Act (19)
Biosimilars (263)
BioSpace Insights (130)
Biotechnology (329)
Bispecific (3)
Bladder cancer (225)
Brain cancer (85)
Breast cancer (869)
Cancer (6958)
Cardiovascular disease (579)
Career advice (1564)
Career pathing (44)
CAR-T (378)
CDC (50)
CDMO (150)
Celiac Disease (4)
Cell therapy (1035)
Cervical cancer (58)
Clinical research (65708)
Collaboration (2335)
Commercialization (11)
Company closure (9)
Compensation (1621)
Complete response letters (102)
COVID-19 (2466)
CRISPR (127)
C-suite (1349)
Cystic fibrosis (167)
Data (9529)
Decentralized trials (3)
Denatured (43)
Depression (204)
Dermatology (134)
Diabetes (766)
Diagnostics (6168)
Digital health (64)
Diversity (13)
Diversity, equity & inclusion (23)
Drug discovery (414)
Drug pricing (201)
Drug shortages (33)
Duchenne muscular dystrophy (332)
Earnings (78571)
Editorial (73)
Employer branding (17)
Employer resources (99)
Events (98700)
Executive appointments (1159)
Eye disease (1)
FDA (18355)
Fibrodysplasia Ossificans Progressiva (12)
Fragile X (1)
Friedreich's ataxia (26)
Frontotemporal dementia (35)
Funding (1960)
Gene editing (266)
Generative AI (77)
Gene therapy (803)
GLP-1 (1316)
Government (3887)
Grass and pollen (6)
Guidances (426)
Healthcare (16062)
Hematology (181)
HIV (110)
Huntington's disease (71)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (136)
Immunology and inflammation (372)
Immuno-oncology (138)
Indications (253)
Infectious disease (2850)
Inflammatory bowel disease (235)
Inflation Reduction Act (17)
Influenza (148)
Intellectual property (326)
Interviews (355)
IPO (15250)
IRA (47)
Job creations (2828)
Job search strategy (1272)
JPM (60)
Kidney cancer (29)
Kidney disease (98)
Labor market (122)
Layoffs (551)
Leadership (49)
Legal (5448)
Licensing (32)
Liver cancer (104)
Longevity (43)
Lung cancer (980)
Lymphoma (510)
Machine learning (62)
Management (35)
Manufacturing (1261)
Marketing (13)
MASH (232)
Medical affairs (3)
Medical device (11495)
Medtech (11717)
Mergers & acquisitions (15513)
Metabolic disorders (1948)
mRNA (243)
Multiple sclerosis (219)
NASH (22)
Netherlands (6)
Neurodegenerative disease (517)
Neuropsychiatric disorders (135)
Neuroscience (3601)
Neurotech (2)
NextGen: Class of 2026 (5224)
Non-profit (3640)
Now hiring (70)
Obesity (921)
Opinion (270)
Ovarian cancer (255)
Pain (301)
Pancreatic cancer (385)
Parkinson's disease (423)
Partnered (40)
Patents (669)
Patient advocacy (1)
Patient recruitment (901)
Patient selection (14)
Peanut (66)
People (39442)
Peptides (9)
Pharmaceutical (80)
Pharmacy benefit managers (32)
Phase 1 (21400)
Phase 2 (28481)
Phase 3 (21580)
Pipeline (11940)
Policy (308)
Postmarket research (2036)
Preclinical (7847)
Press Release (72)
Prostate cancer (363)
Psychedelics (78)
Radiopharmaceuticals (349)
Rare diseases (1347)
Real estate (4175)
Recruiting (46)
Regenerative medicine (6)
Regulatory (21960)
Reports (63)
Research institute (2072)
Resumes & cover letters (345)
Rett syndrome (52)
RNA editing (30)
RSV (90)
Schizophrenia (205)
Series A (322)
Series B (240)
Service/supplier (15)
Sickle cell disease (126)
Special edition (36)
Spinal muscular atrophy (183)
Sponsored (53)
Startups (2532)
State (1)
Stem cells (1)
Stomach cancer (20)
Substance use disorders (20)
Supply chain (134)
Tariffs (89)
The Weekly (119)
Vaccines (1170)
Venture capital (128)
Weight loss (618)
Women's health (150)
Worklife (19)
Date
Today (127)
Last 7 days (554)
Last 30 days (2422)
Last 365 days (30264)
2026 (22267)
2025 (30213)
2024 (33061)
2023 (35020)
2022 (44422)
2021 (47182)
2020 (44740)
2019 (37429)
2018 (28350)
2017 (26839)
2016 (24775)
2015 (29420)
2014 (21592)
2013 (17152)
2012 (18035)
2011 (18769)
2010 (17065)
Location
Africa (636)
Alabama (98)
Alaska (6)
Arizona (327)
Arkansas (10)
Asia (35115)
Australia (5880)
California (14921)
Canada (4083)
China (1726)
Colorado (615)
Connecticut (669)
Delaware (469)
Europe (80267)
Florida (2264)
Georgia (456)
Hawaii (5)
Idaho (49)
Illinois (1216)
India (130)
Indiana (668)
Iowa (31)
Japan (674)
Kansas (144)
Kentucky (59)
Louisiana (63)
Maine (89)
Maryland (1719)
Massachusetts (10790)
Michigan (362)
Minnesota (764)
Mississippi (7)
Missouri (156)
Montana (32)
Nebraska (20)
Nevada (161)
New Hampshire (75)
New Jersey (4019)
New Mexico (29)
New York (3891)
North Carolina (1888)
North Dakota (9)
Northern California (7532)
Ohio (448)
Oklahoma (23)
Oregon (42)
Pennsylvania (2837)
Puerto Rico (35)
Rhode Island (49)
South America (930)
South Carolina (89)
South Dakota (2)
Southern California (5985)
Tennessee (233)
Texas (2424)
United States (52347)
Utah (437)
Vermont (2)
Virginia (369)
Washington D.C. (75)
Washington State (1192)
West Virginia (4)
Wisconsin (166)
Wyoming (3)
584,544 Results for "confidential 1".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
IPO
Obesity newcomer Kalohexis makes confidential IPO bid 3 months after spinoff
Kalohexis is working on peptide therapies, including one for obesity that could offer an alternative approach to the GLP-1s that currently dominate the weight loss space.
July 8, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Sensorion Announces Confidential Submission of Draft Registration Statement to the SEC for Potential U.S. Initial Public Offering
September 16, 2026
·
1 min read
Press Releases
Kalohexis Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
July 7, 2026
·
1 min read
Legal
Vanda Loses Confidentiality Complaint Over FDA’s Talks With Generics Developers
The U.S. Court of Federal Claims ruled that Vanda cannot claim a breach of confidentiality for specifications that it did not develop itself.
January 23, 2025
·
2 min read
·
Tristan Manalac
Press Releases
AINN-P1: Small Model, Big Intelligence
AINN-P1: Small Model, Big IntelligenceHow does a 167M-parameter protein foundation model outperform a 650M general-purpose model on the tasks that matter?
September 10, 2026
·
1 min read
Press Releases
Slate Medicines Announces First Participant Dosed in Phase 1 Study Evaluating SLTE-1009
August 27, 2026
·
5 min read
GLP-1
Lilly presents early data supporting GLP-1/GIP candidate’s potential in depression, alcohol use disorder
With a trillion-dollar market cap and a wildly successful GLP-1 portfolio, Eli Lilly isn’t resting on its laurels. At the Psych Congress 2026, the company presented early-stage data that could support the potential of its next-gen GLP-1 and GIP receptor agonist to treat diseases far beyond obesity.
September 22, 2026
·
5 min read
·
Heather McKenzie
Press Releases
Hemostemix’ $1,000,000 Private Placement and Update
June 18, 2026
·
10 min read
Venture capital
Frazier adds $1.1B+ to small and mid-sized biotech fund
Frazier’s life science fund has already benefited several successful biotechs, including Verona Pharma, which was acquired by Merck for $10 billion, and Carmot Therapeutics, which Roche bought for $2.7 billion.
September 11, 2026
·
2 min read
·
Tristan Manalac
Obesity
Structure’s obesity portfolio impresses on GLP-1 and amylin fronts in dual data drop
Structure Therapeutics’ oral GLP-1 candidate aleniglipron showed 72-week efficacy “in line” with Novo Nordisk’s oral Wegovy, BMO Capital Markets wrote in a note to investors. Meanwhile, Structure’s amylin and calcitonin receptor agonist ACCG-2671 showed “impressive” target engagement in a Phase 1 trial of healthy volunteers, according to Leerink Partners.
September 8, 2026
·
2 min read
·
Heather McKenzie
1 of 58,455
Next